Hyperpolarized Imaging in Diagnosing Participants With Glioma

ConditionGlioma
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age19+
SponsorSusan Chang

About this trial

This pilot trial studies the side effects of hyperpolarized carbon C 13 pyruvate magnetic resonance imaging (MRI) in diagnosing participants with glioma. Diagnostic procedures, such as hyperpolarized carbon C 13 pyruvate MRI, may help find and diagnose glioma.

Eligibility criteria

Qualifiers

Participants must be > 18 years old and with a life expectancy > 12 weeks.

Participants must have a Karnofsky performance status of ≥ 60.

Participants must have adequate renal function (creatinine < 1.5 mg/dL) before starting therapy. This tests must be performed within 60 days prior to Hyperpolarized Imaging scan.

Participants must not have any significant medical illnesses that in the investigator's opinion cannot be adequately controlled with appropriate therapy, would compromise the patient's ability to tolerate the imaging examination or any disease that will obscure toxicity or dangerously alter response to the imaging agent.

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Hyperpolarized Carbon C 13 Pyruvate
  • Magnetic Resonance Imaging
  • Radiation Therapy
  • Chemotherapy

Treatment groups

140 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Susan Chang

Lead sponsor

University of California, San Francisco

Sponsor institution

National Cancer Institute (NCI)

Collaborator